Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Dr. Hoos Discusses Patients Eligible to Receive Ipilimumab

Axel Hoos, MD, PhD
Published: Wednesday, Aug 03, 2011

Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb, discusses that the ipilimumab (Yervoy) label is very broad and includes both pretreated and untreated metastatic melanoma. No subset of patients has been identified that will not benefit from the drug. Evaluating prognostic information reveals that survival benefits has been found in all groups.
SELECTED
LANGUAGE
Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb, discusses that the ipilimumab (Yervoy) label is very broad and includes both pretreated and untreated metastatic melanoma. No subset of patients has been identified that will not benefit from the drug. Evaluating prognostic information reveals that survival benefits has been found in all groups.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x